{
    "Trade/Device Name(s)": [
        "CONFIRM anti-Progesterone Receptor (1E2) Rabbit Monoclonal Primary Antibody"
    ],
    "Submitter Information": "Ventana Medical Systems, Inc.",
    "510(k) Number": "K103818",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020023"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXZ"
    ],
    "Summary Letter Date": "November 16, 2011",
    "Summary Letter Received Date": "October 27, 2011",
    "Submission Date": "October 26, 2011",
    "Regulation Number(s)": [
        "21CFR864.1860"
    ],
    "Regulation Name(s)": [
        "Immunohistochemistry reagents and kits"
    ],
    "Analyte Class(es)": [
        "anatomic pathology",
        "immunology"
    ],
    "Analyte(s)": [
        "Progesterone Receptor (PR)"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VENTANA automated slide stainer",
        "BenchMark ULTRA",
        "BenchMark XT"
    ],
    "Method(s)/Technology(ies)": [
        "Immunohistochemistry"
    ],
    "Methodologies": [
        "Qualitative detection",
        "Antibody-based staining"
    ],
    "Submission Type(s)": [
        "Antibody",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for CONFIRM anti-Progesterone Receptor (1E2) Rabbit Monoclonal Primary Antibody for qualitative detection of PR in breast cancer tissue sections using immunohistochemistry.",
    "Indications for Use Summary": "Intended for qualitative detection of progesterone receptor antigen in formalin-fixed, paraffin-embedded tissue sections to aid in management, prognosis, and prediction of hormone therapy for breast carcinoma, using VENTANA automated slide stainers and detection kits.",
    "fda_folder": "Hematology"
}